-
-
-
Chairman, Celltrion Group
Seo Jung-jin
Driven Strategist Targets New-Drug Leadership Beyond Biosimilars
-
Last Updated on Sep 9, 2026
Seo Jung-jin is chairman of Celltrion Group.
He is pushing to transform Celltrion from a biosimilar company into a new drug developer.
He was born in Cheongju, North Chungcheong Province, on October 23, 1957.
He graduated from Jemulpo High School in Incheon and Konkuk University with a degree in industrial engineering. He earned a master's degree from the Graduate School of Industrial Engineering at Konkuk University.
He worked at Samsung Electro-Mechanics. While handling consulting for Daewoo Motor at the Korea Productivity Center, he was recruited as an adviser to Daewoo Motor.
When Daewoo Group was dismantled in the wake of the IMF financial crisis, he founded Nexol, the predecessor of Celltrion, with former Daewoo Motor colleagues in 1999 and entered the biosimilar business.
He developed Remsima, the world's first antibody biosimilar.
He stepped down from management in 2020 after establishing a professional management system at Celltrion Group, but returned in 2023.
He is a strong workaholic and is known for his drive.